Filing Flows

Filing Flows › Companies › Coya Therapeutics › Cash flow

Coya Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.4M in Q2 2026 · −$15.7M over twelve months

Operating cash flow−$7.4M
Free cash flow−$7.4M

Analysis

In Q2 2026, Coya Therapeutics generated −$7.4M of operating cash flow. That is $1.6M less than in Q2 2025 (−$5.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$15.7M; the largest uses were operating cash flow ($15.7M); besides operations, cash came from other financing ($31.2M); the cash balance rose by $13.4M.

Operating cash flow was −$7.4M against net income of −$6.6M. The largest differences: prepaid and other assets −$1.2M, stock-based pay +$944K, deferred revenue −$244K.

Free cash flow

Coya Therapeutics: free cash flow by quarterCoya Therapeutics: free cash flow by quarter−$5.5MQ3 2024−$2.4MQ4 2024−$2.8MQ1 2025−$5.8MQ2 2025−$1.1MQ3 2025−$1.0MQ4 2025−$6.2MQ1 2026−$7.4MQ2 2026
Operating cash flow less capital spending.
Coya Therapeutics: operating cash flow against capital spendingCoya Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$5.5M$0Q3 2024−$2.4M$0Q4 2024−$2.8M$0Q1 2025−$5.8M$0Q2 2025−$1.1M$0Q3 2025−$1.0M$0Q4 2025−$6.2M$0Q1 2026−$7.4M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$7.4M, Capital spending $0.

Capital allocation, year by year

Coya Therapeutics: where the cash came from (up) and went (down), by fiscal yearCoya Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2021: Operating cash flow −$3.9MFY2021: Shares issued $317$317FY2021FY2022: Operating cash flow −$7.2MFY2022: Net borrowing $10.5MFY2022: Shares issued $158$10.5MFY2022FY2023: Operating cash flow −$11.2MFY2023: Shares issued $14.3M$14.3MFY2023FY2024: Operating cash flow −$10.3MFY2024: Shares issued $14.0M$14.0MFY2024FY2025: Operating cash flow −$10.7MFY2025: Shares issued $20.4M$20.4MFY2025
Over these 5 years operating cash flow totalled −$43.4M; the largest uses were operating cash flow ($43.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$43.2M
Debtnone
Net cash$43.2M
Cash runway2.7 years

Coya Therapeutics is burning cash: its operations consume cash, a free cash flow of −$15.7M a year at the current rate against $43.2M of cash and investments: a runway of about 2.7 years before any new financing.

Where the cash came from and went

Coya Therapeutics: sources (+) and uses (−) of cash, Q2 2026Coya Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$7.5MOperating cash flow−$7.4MOther financing−$124KShares issued−$42KOther investing−$2K
Coya Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Coya Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$31.2MOperating cash flow−$15.7MCash drawn (+) / kept (−)−$13.4MNot reconciled−$2.1M

From profit to cash

Coya Therapeutics: net income to operating cash flow, Q2 2026Coya Therapeutics: net income to operating cash flow, Q2 2026Net income−$6.6MDepreciation & amortization$3KStock-based pay$944KPayables$59KAccrued liabilities−$162KDeferred revenue−$244KPrepaid and other assets−$1.2MOperating cash flow−$7.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$7.4M−$42K$7.5M−$7.4M
Q1 2026−$6.2M$11.0M−$3.9M−$6.2M
Q4 2025−$1.0M—−$18.7M−$1.0M
Q3 2025−$1.1M$19K$1.6M−$1.1M
Q2 2025−$5.8M—$5.8M−$5.8M
Q1 2025−$2.8M$19K$2.8M−$2.8M
Q4 2024−$2.4M$9.1M−$7.3M−$2.4M
Q3 2024−$5.5M−$56K$5.5M−$5.5M

Coya Therapeutics: income statement and cash flow

Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year). The chart follows the revenue to costs, profit and cash.

Coya Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.